Equities research analysts expect AxoGen, Inc. (NASDAQ:AXGN) to post ($0.11) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for AxoGen’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.15). AxoGen also reported earnings of ($0.11) per share in the same quarter last year. The business is expected to announce its next quarterly earnings report on Thursday, May 3rd.
On average, analysts expect that AxoGen will report full-year earnings of ($0.28) per share for the current financial year, with EPS estimates ranging from ($0.38) to ($0.20). For the next financial year, analysts expect that the business will report earnings of ($0.10) per share, with EPS estimates ranging from ($0.26) to $0.09. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover AxoGen.
AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The business had revenue of $16.97 million for the quarter, compared to the consensus estimate of $16.38 million. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The firm’s revenue was up 48.7% compared to the same quarter last year. During the same period last year, the company earned ($0.10) EPS.
A number of research analysts have recently issued reports on AXGN shares. Jefferies Group started coverage on shares of AxoGen in a research report on Thursday, November 30th. They issued a “buy” rating and a $35.00 price target on the stock. Cantor Fitzgerald set a $37.00 price target on shares of AxoGen and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. Lake Street Capital set a $38.00 price target on shares of AxoGen and gave the stock a “buy” rating in a research report on Friday, March 2nd. Finally, Wedbush restated a “buy” rating and issued a $27.00 price target (up previously from $22.00) on shares of AxoGen in a research report on Tuesday, November 21st. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $33.14.
Shares of AxoGen stock traded up $0.65 during midday trading on Tuesday, hitting $38.50. 349,335 shares of the stock were exchanged, compared to its average volume of 332,369. The firm has a market cap of $1,298.81, a P/E ratio of -128.33 and a beta of 0.10. AxoGen has a 1 year low of $9.95 and a 1 year high of $39.10. The company has a quick ratio of 3.53, a current ratio of 4.07 and a debt-to-equity ratio of 0.79.
In other news, CFO Jamie Mark Grooms sold 95,712 shares of AxoGen stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $26.84, for a total value of $2,568,910.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 169,407 shares of company stock valued at $4,593,013 in the last quarter. 9.33% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co bought a new stake in shares of AxoGen in the 4th quarter valued at $215,000. Guggenheim Capital LLC bought a new stake in shares of AxoGen in the 4th quarter valued at $228,000. Gotham Asset Management LLC bought a new stake in shares of AxoGen in the 4th quarter valued at $249,000. Teacher Retirement System of Texas bought a new stake in shares of AxoGen in the 4th quarter valued at $271,000. Finally, Valeo Financial Advisors LLC bought a new stake in shares of AxoGen in the 3rd quarter valued at $244,000. Institutional investors own 67.97% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “-$0.11 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/20/0-11-earnings-per-share-expected-for-axogen-inc-axgn-this-quarter.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.